Rocket Pharmaceuticals Inc (NAS:RCKT)
$ 21.3 -0.13 (-0.61%) Market Cap: 1.93 Bil Enterprise Value: 1.64 Bil PE Ratio: 0 PB Ratio: 4.38 GF Score: 39/100

Rocket Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 11:20PM GMT
Release Date Price: $20.93 (+1.26%)
Gregory Allen Harrison
BofA Securities, Research Division - Analyst

(technical difficulty) and welcome to Day 2 of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And this afternoon, we have Rocket Pharma here with us with Gaurav Shah, the Chief Executive Officer. Gaurav is going to make a couple of opening remarks, and we'll jump into Q&A.

Gaurav D. Shah
Rocket Pharmaceuticals, Inc. - CEO & Director

Thanks, Greg, for having us here. It's a wonderful conference each time. This is a year, where I believe we're going to see a lot of progress with gene therapy in general, certainly at Rocket, but across both AAV and lenti with other companies. We're very excited Rocket specifically, is poised on becoming commercial soon in 2024. So we're in a transition period from being an R&D company into being a full-on commercial company with integrated manufacturing. So we're very excited about that. We have some key inflection points, I would say, in the next 12 months around Danon, Fanconi, LAD, PKD and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot